Search Results

Innovative Approaches in GPCR Drug Discovery: Designing Precise Solutions for GPCR Challenges. Career opportunities:  Discovery biology roles and training paths in GPCR signaling. Terry’s Corner: Why Chemistry Still Rules For decades, discovery focused on targets. What You’ll Learn on molecular creativity in drug discovery: • Why Nature Was First : From opium to antibiotics GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Why I Started GPCR Consulting You've got great data. You've got brilliant scientists. But your GPCR program still isn't moving at the pace it should. I've seen this pattern unfold across biotech, academia, and nonprofits. The assays are running, data is flowing in from your CROs or your internal labs , yet progress stalls. Decisions are slow, crucial data is siloed, and despite everyone working hard, programs drift. For over two decades, my work has centered on GPCR pharmacology . In every role and sector, I found myself drawn to the same critical challenges: missed opportunities, misaligned systems, and promising programs stalling despite strong science. I was always the one identifying what could be improved: The essential structure that was missing. The clarity that was desperately lacking. The unnecessary friction that slowed everything down. Traditional roles rarely gave me the freedom to implement these changes at the scale needed. So, I created a new path—one that allows me to embed, optimize, and accelerate GPCR programs from the inside out. The GPCR Data Dilemma: The Lego Bucket Problem I've seen promising GPCR programs generate massive volumes of high-quality data. But without structure, it's just a messy pile of colored blocks. I call this the Lego Bucket Problem . You have the data, but not the definitive direction. This disconnect frequently leads to: Underperforming assays. Internal data and CRO outputs  misaligned with strategic goals. Delays in critical go/no-go decisions. Frustrated teams and slipping timelines. It's not just a scientific issue—it's an operational one. You can't move fast without clarity, and you can't make confident decisions without robust structure. My Approach: Biology, Execution, Systems My consulting approach uniquely blends deep pharmacology expertise with the operational discipline required to make that expertise actionable. Here's how I bring a fresh perspective: Biology-First, Data-Driven Strategy:  I help you focus on the science that truly matters. We cut through the noise, elevate what's working, and strategically solve what's not, ensuring your GPCR program stays on target. Embedded Execution:  I work alongside your team—not above it. I'll help write CRO scopes, meticulously review assay data, flag risks early, and keep your programs relentlessly on track. Systems That Drive Progress:  From assay tracking to data workflows, I design simple, scalable tools that surface insights early and dramatically reduce delays, transforming your data into actionable intelligence. A Broader Lens: Dr. GPCR As the co-founder of Dr. GPCR, we've built a global hub connecting over 1,300 GPCR scientists dedicated to this field. These ongoing conversations keep me on the front lines, sharpening my understanding of the common bottlenecks and evolving needs across the entire GPCR community. My Consulting Philosophy This practice is built on three core values: Scientific Integrity:  Every recommendation is grounded in real-world evidence and extensive experience. Operational Discipline:  Robust systems and clear structure aren't "nice to have"—they are absolutely essential for efficient progress. Collaborative Partnership:  I embed, contribute, and build solutions hand-in-hand with your team. Ready to Move Your GPCR Program Forward? If you're navigating a stuck GPCR program, planning your next crucial milestone, or struggling to gain clarity from complex data, I'd love to help. 📌 Learn more about my services: Yamina.org 📅 Book a 30-minute strategy call: https://calendly.com/drgpcr/yamina-corner

Sharpen your discovery decisions ➤ Yamina’s Corner - The Hidden Cost of Busy A GPCR program can collapse—not Read the article now ➤ Discovery on Target - The Next Wave of GPCR Drug Discovery The 20th Annual GPCR-Based Drug Discovery Conference  isn’t just another event—it’s where the frameworks shaping the next decade GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need Aside from his vast experience in drug development, not to mention his extensive publication record,

The Overlooked Step in Every Discovery Program So what does that mean for discovery scientists designing By visualizing enzymes as dynamic molecular partners rather than static filters, drug discovery scientists And responsible for countless drug–drug interactions. Kenakin live for an open Q&A session designed for discovery scientists. That’s where Terry’s Corner  gives discovery teams an edge.

Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches for the success of drug discovery, just as much as choosing the right targets. Their integration into drug discovery neuroscience workflows helps accelerate GPCR target identification Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches

Discovery programs rarely fail because a molecule “did nothing.” It was revealed only when the drug encountered the full complexity of the cardiovascular regulatory network Kenakin talked about  the specific allosteric properties orthosteric drugs cannot offer. Why Terry’s Corner Give You The GPCR Pharmacology Insights You Need Terry’s Corner gives discovery scientists It equips pharmacologists, discovery teams, and biotech leaders to see around mechanistic corners, recognize

In the high-stakes world of GPCR drug discovery , breakthrough science isn't enough. The Role of Systems Thinking in GPCR Drug Discovery Systems thinking is the intentional practice of seeing I'll show you how to transform your drug discovery process from a series of disconnected efforts into is strategic and sustainable, offering precision scientific and operational guidance  to accelerate discovery

Pipeline Efficiency Begins With the Chemistry Itself Drug discovery pipelines often stall not because This lesson asks a deceptively simple question: What if our molecules—not our targets—are limiting discovery design The Long Arc of Chemical Pharmacology The early history of drug discovery was rooted in nature Allostery and Biased Signaling Change the Game The most profound change in GPCR drug discovery is our Members can also propose new topics, ensuring relevance to real-world discovery problems.

🔹 Elevate your strategy → Building clarity in GPCR drug discovery Even the strongest GPCR programs GPCR Podcast - Surviving Discovery’s Gauntlet Dr. Sokhom Pin delivers brutally honest insights.   Find your edge:  Dodge the traps that derail real drug discovery careers.  

Why Speed Matters in GPCR Drug Discovery Nine out of ten GPCR programs stall  not because the target In accelerating GPCR drug discovery, the bottleneck isn’t target identification — it’s turning validated That’s exactly what Terry’s Corner  was built to do: bring four decades of frontline discovery insight straight to discovery-phase scientists and R&D strategists — without the noise, hype, or outdated models For scientists in discovery, this means two things: Technical clarity drives survival.

on Target GPCR Drug Discovery. 🔍 This Week in Premium: Sneak Peek A curated preview of this week’s Upcoming events:  5th MMCS New Trends in Drug Discovery; GPCR-UK Network Meeting; neuroGPCR Symposium Terry’s Corner: Why Binding Kinetics Matter More Than Affinity In drug discovery today, time wasted is on Target GPCR-Based Drug Discovery  meeting is where the next wave of therapies—from allosteric modulators GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Every delay in the discovery pipeline compounds into wasted years, lost opportunities, and soaring costs For GPCR drug discovery, those hidden details can determine whether a compound advances or stalls. For discovery teams, this isn’t an academic exercise. Pipeline Payoff: Assay Sensitivity for Better Predictions For drug discovery scientists, time and predictive Here, you’ll get: Weekly lectures  that sharpen the exact tools you rely on in discovery.

This lecture is a roadmap for understanding why two drugs with similar affinity may behave completely Discovery For decades, drug discovery pipelines have relied on the orthosteric model: one ligand, one But without understanding how GPCR state changes  influence that affinity—or vice versa—drug discovery Terry’s Pharmacology Corner  delivers trusted, razor-sharp insight to help drug discovery professionals Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to shape future topics Built for discovery-phase

Meetings drag. Decisions stall. And momentum quietly dies.

It has particular relevance in the field of drug discovery, offering transformative potential across Target Identification and Validation In drug discovery, the identification of robust drug targets is Predicting and Overcoming Drug Resistance A significant challenge in drug development, particularly in In conclusion, deep mutational scanning is a versatile tool in drug discovery, providing detailed insights Predicting Drug Resistance Using Deep Mutational Scanning.

GPCR research requires turning data into insights for drug discovery Hi GPCR Friends, Every week, critical Terry's Corner – Curve Shifts Don’t Lie, But Your Eyes Might In early drug discovery, “those curves look When the global biotech crowd lands in Boston for Discovery on Target. Whether you’re in discovery, translation, or strategic leadership, Premium ensures you never fall behind GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Terry's Corner – Assay Volume Control in GPCR Drug Discovery This week in Terry’s Corner, you’ll learn discovery program. Your membership gives you:   Proven   frameworks  for real-world GPCR drug discovery Flexible , on-demand discovery. GPCR scientists, translational pharmacologists, discovery teams, and decision-makers who need fast, curated

For drug discovery teams and scientists, staying ahead requires more than just reading papers—it demands Terry's Corner : Unlock the Power of Intracellular GPCR Drugs For years, GPCR drug discovery has focused GPCR Podcast : The Future of GPCR Drug Discovery with Molecular Modeling The field of GPCR research is discovery. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

GPCR and global experts at the GPCR Drug Discovery session during Discovery on Target 2025—where groundbreaking GPCR Drug Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery And at this year’s Discovery on Target  meeting in Boston, the GPCR Drug Discovery track will deliver 2025 🎯 Track:   GPCR Drug Discovery Let’s connect. Let’s move GPCR drug discovery forward — together. 🚨 Mark your calendar for the GPCR Happy Hour Join

A rational drug discovery campaign hinges on a deep understanding of how distinct molecules interact While these structural techniques offer significant advantages in drug discovery, no single method can However, several challenges have limited the use of mutagenesis in drug discovery. In summary, mutagenesis can be a critical tool in drug discovery, particularly for studying GPCRs. discovery.

Are you ready to truly understand how pharmacologists predict whole-body drug response from a single Probability Models   This is practical drug development expertise from Terry’s 40+ years of experience

Different reviews have extensively described the success and failure in drug discovery on chemokine receptors There are only two drugs in the market targeting chemokine receptors: maraviroc, an allosteric and reversible This redundancy can be seen as problematic in drug discovery as blocking a single receptor might not Another important aspect in CKRs targeted drug discovery is the concept of biased agonism/antagonism, Drug discovery is shifting towards the development of biased ligands, which promote the engagement of

targets and designing effective drug molecules. However, the impact on structure-based ligand discovery remained uncertain due to the necessity for accurately This validates AF2's potential in enhancing drug discovery precision and efficiency. Addressing these challenges is crucial to fully harness AI's potential in accelerating drug discovery AlphaFold2 structures guide prospective ligand discovery.

Enhancing scientific exploration by concentrating on understanding inhibition to advance GPCR drug discovery Terry's Corner – How Enzyme Inhibition Shapes Every Discovery Program Every molecule meets an enzyme Mastering inhibition isn’t just about avoiding drug–drug interactions. Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

GPCR Updates Learn Pharmacology That Drives Discovery  – From Dr. oncogenic signaling in lymphoid neoplasms, and its disruption boosts sensitivity to the apoptosis-inducing drug

In his view, collaboration is not a bonus or an optional supplement—it is the only way GPCR drug discovery Many startups chase elaborate simulations that look impressive on paper but do little to move drug discovery discovery. The path forward depends on knitting these pieces together into a coherent discovery engine. Carlsson’s lesson is simple but profound: the strongest model in GPCR drug discovery isn’t built on a

Exploring ORs in drug discovery – opportunities and threats Given the functional relevance of ORs in need to identify selective agonists or antagonists, where the starting point can be using licensed drugs (for drug repurposing) and endogenous ligands. discovery. Future directions Important directions in ORs research to advance drug discovery include the deorphanization

Hiring Won’t Save Your GPCR Drug Discovery Program When a drug discovery program stalls, the default Bad Data Management Is Undermining Your GPCR Drug Discovery Team The real problem isn’t competence. Without a unified drug discovery data management  pipeline, teams waste hours cleaning, reconciling, Build Precision Systems for GPCR Drug Discovery The only way out for GPCR drug discovery programs isn Because the truth is harsh: in drug discovery, you don’t run out of science. You run out of money.

discovery. discovery, and biophysics, ensuring you don't miss crucial networking and learning opportunities. Terry's Corner - Unlock the Power of Target Residence Time in Your GPCR Drug Discovery Pipeline Gain discovery. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

depression, schizophrenia and Parkinson’s disease. [1,2] Several dopamine ligands have been approved as drugs Therefore, both assays can be used for fundamental D3 receptor-ligand binding studies as well as for drug methods can increase the quality and quantity of both fundamental receptor research and high-throughput drug Current Drug Treatments Targeting Dopamine D3 Receptor.